Cambiar Investors LLC Sells 17,850 Shares of Maximus, Inc. (NYSE:MMS)

Cambiar Investors LLC decreased its holdings in Maximus, Inc. (NYSE:MMS) by 13.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 114,120 shares of the health services provider’s stock after selling 17,850 shares during the quarter. Cambiar Investors LLC’s holdings in Maximus were worth $8,519,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MMS. V Square Quantitative Management LLC bought a new position in Maximus in the third quarter worth approximately $25,000. UMB Bank n.a. raised its stake in Maximus by 79.8% in the fourth quarter. UMB Bank n.a. now owns 356 shares of the health services provider’s stock worth $27,000 after buying an additional 158 shares in the last quarter. Eastern Bank bought a new position in Maximus in the fourth quarter worth approximately $29,000. R Squared Ltd bought a new position in Maximus in the fourth quarter worth approximately $54,000. Finally, GAMMA Investing LLC raised its stake in Maximus by 150.6% in the third quarter. GAMMA Investing LLC now owns 862 shares of the health services provider’s stock worth $80,000 after buying an additional 518 shares in the last quarter. Institutional investors own 97.21% of the company’s stock.

Insider Activity

In other Maximus news, CEO Bruce Caswell purchased 3,500 shares of the stock in a transaction on Tuesday, December 17th. The shares were bought at an average cost of $70.64 per share, with a total value of $247,240.00. Following the completion of the acquisition, the chief executive officer now owns 275,929 shares in the company, valued at $19,491,624.56. This trade represents a 1.28 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Michelle F. Link sold 2,208 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $73.83, for a total transaction of $163,016.64. Following the completion of the sale, the insider now directly owns 6,567 shares in the company, valued at approximately $484,841.61. The trade was a 25.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have purchased 7,063 shares of company stock valued at $502,017 over the last ninety days. 1.60% of the stock is currently owned by insiders.

Maximus Stock Performance

Shares of MMS stock opened at $69.75 on Tuesday. The business’s fifty day simple moving average is $74.64 and its 200-day simple moving average is $83.12. The company has a market cap of $3.98 billion, a PE ratio of 15.00 and a beta of 0.72. The company has a current ratio of 1.72, a quick ratio of 1.49 and a debt-to-equity ratio of 0.82. Maximus, Inc. has a 12-month low of $68.15 and a 12-month high of $93.97.

Maximus (NYSE:MMS) last issued its quarterly earnings results on Thursday, February 6th. The health services provider reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%. Analysts expect that Maximus, Inc. will post 6.05 earnings per share for the current fiscal year.

Maximus Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 28th. Stockholders of record on Saturday, February 15th will be issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date of this dividend is Friday, February 14th. Maximus’s dividend payout ratio (DPR) is presently 25.81%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. StockNews.com raised Maximus from a “hold” rating to a “buy” rating in a research report on Thursday, February 6th. Raymond James raised Maximus from a “market perform” rating to an “outperform” rating and set a $90.00 price target on the stock in a research report on Thursday, January 2nd.

Maximus Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.